Inlyta® (axitinib) Tablets for Advanced Kidney Cancer

What Inlyta® Is and How It Works

Inlyta (axitinib) is an oral tyrosine kinase inhibitor used for adults with advanced renal cell carcinoma (RCC). It is supplied in multiple strengths, including Inlyta 5 mg tablets taken twice daily. Many patients compare Inlyta 5 mg price to plan therapy, including those exploring inlyta without insurance options. The inlyta manufacturer is Pfizer.

Inlyta blocks vascular endothelial growth factor receptors (VEGFR‑1, VEGFR‑2, VEGFR‑3). This axitinib target reduces tumor blood supply and can slow cancer growth. Inlyta is used alone after prior therapy or in combination with immune checkpoint inhibitors for first‑line RCC. YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing.

In clinical studies, Inlyta improved progression‑free survival. It is taken by mouth and does not require infusion visits. This inlyta medication is film‑coated and taken about 12 hours apart, with flexible dosing based on tolerability and response.

Dosage and Usage

• Typical starting dose: 5 mg by mouth twice daily, about 12 hours apart, with or without food.
• Swallow tablets whole with water; do not crush, split, or chew.
• Titration: may increase to 7 mg twice daily, then to 10 mg twice daily if tolerated. Reduce dose for adverse effects.
• Concomitant medications: reduce dose with strong CYP3A4 inhibitors; consider higher doses with strong inducers per prescriber guidance.
• Missed dose: skip and take the next scheduled dose; do not double up. If vomiting occurs after a dose, do not re‑dose.
• Blood pressure: monitor regularly; manage hypertension before and during therapy.
• Food and beverages: avoid grapefruit or grapefruit juice.
• Surgery and wound healing: hold before major surgery and resume only when adequate healing has occurred, per prescriber direction.
• Pregnancy: can cause fetal harm; use effective contraception during treatment and for a period after the last dose as advised.
• Liver or kidney concerns: dose adjustments may be needed in hepatic impairment; follow specialist guidance.

• Store at 20–25 °C (68–77 °F); excursions 15–30 °C (59–86 °F) are acceptable.
• Keep tablets dry in the original, tightly closed container.
• Protect from excessive heat, moisture, and light.
• Keep out of reach of children and pets.
• For travel, carry your medication in your hand luggage with the original label and prescription copy.
• Do not store in a car glove box or in checked luggage.
• If a pill organizer helps, you can use one; keep desiccant with the original bottle.
• Set phone reminders so you take doses about 12 hours apart.

Benefits and Savings

Inlyta offers proven efficacy for RCC with oral dosing convenience. Flexible titration helps balance benefit and tolerability. When combined with immune therapy, it supports first‑line options endorsed in current guidelines. Patients often compare Inlyta 5mg cost when selecting a regimen that fits medical needs and budget.

Ordering from Canadian pharmacy pricing can mean 60–80% savings versus typical US prices. This can lower inlyta cash price and out‑of‑pocket exposure. Many patients ask about inlyta no insurance or inlyta uninsured scenarios; our team can outline supply options and receipt documentation for your records.

We work with licensed, vetted partner pharmacies internationally to provide authentic brand medications with a broad selection at affordable pricing. For extra offers, see our Inlyta coupon page for current promotions.

Side Effects and Safety

• Common inlyta 5 mg side effects: high blood pressure, diarrhea, fatigue, nausea, decreased appetite.
• Dysphonia (voice changes), headache, weight loss, taste changes.
• Hand‑foot skin reaction (palmar‑plantar erythrodysesthesia), rash.
• Stomatitis/mouth sores, abdominal pain, indigestion.
• Hypothyroidism or other thyroid function changes.
• Proteinuria and edema.
• Elevated liver enzymes.

Serious risks can include hemorrhage, arterial or venous thromboembolic events, heart failure, gastrointestinal perforation or fistula, hypertensive crisis, posterior reversible encephalopathy syndrome (PRES), and impaired wound healing. Stop treatment and seek urgent care for signs of severe bleeding, chest pain, sudden neurologic symptoms, or severe headache/vision changes. Avoid pregnancy and breastfeeding during therapy and for the advised period after the last dose.

Onset Time

Blood pressure increases may appear within days to weeks, so early monitoring is essential. Symptom changes can occur within the first few weeks as dosing stabilizes. Radiologic assessment for tumor response is often done around 6–12 weeks, then at regular intervals. Some patients achieve durable disease control for months or longer, depending on disease biology and combination therapy.

Compare With Alternatives

Other VEGF‑pathway TKIs for RCC include sunitinib (Sutent), pazopanib (Votrient), and cabozantinib (Cabometyx). Each has distinct dosing schedules and side‑effect profiles. Choice depends on prior therapy, risk group, comorbidities, and whether immunotherapy will be combined.

First‑line options often pair a TKI with an immune checkpoint inhibitor. Avelumab plus axitinib is one such regimen; see Bavencio® for details on the PD‑L1 component. For other cancers, therapies like Zytiga® (prostate cancer) or Xospata® (acute myeloid leukemia) address different diseases and are not alternatives for RCC. If needed, ask about oncology options beyond RCC.

Combination Therapy

• Axitinib + pembrolizumab: first‑line RCC; monitor for immune‑related adverse events and overlapping toxicities.
• Axitinib + Bavencio®: another first‑line option; coordinate monitoring across both agents.
• When combining with immunotherapy, adjust axitinib dose to reduce overlapping side effects like fatigue, diarrhea, or liver enzyme elevations.
• Blood pressure control is crucial before and during combination therapy.
• Hold axitinib ahead of major surgery to reduce wound‑healing complications; restart when clinically appropriate.

Patient Suitability and Cost-Saving Tips

Inlyta is intended for adults with advanced RCC, either after prior systemic therapy or as part of first‑line combination regimens. Not all patients are candidates. Those with uncontrolled hypertension, recent significant bleeding, severe hepatic impairment, or recent major surgery may not be suitable. It is contraindicated in pregnancy and not recommended during breastfeeding.

Inlyta is not approved for lung cancer or melanoma. Searches for “Inlyta for lung cancer” or “Inlyta for melanoma” reflect research interest, but current approvals focus on RCC. Discuss goals of care, risks, and alternatives with an oncology specialist.

To manage costs, you can set reorder reminders so you never run out. Multi‑month supplies can lower per‑month costs when appropriate. Patients comparing inlyta out of pocket options can often reduce expenses by choosing longer fills when stable on therapy. If needed, our team can discuss inlyta without insurance ordering and receipts for HSAs/FSAs.

Authoritative Sources

Pfizer product information for Inlyta

FDA Prescribing Information (axitinib)

Health Canada Drug Product Database: Inlyta

Order Inlyta® from Youdrugstore.com: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is educational and does not replace advice from your healthcare professional. Always follow your prescriber’s directions and local guidelines.